Estrogen Deficiency on Cardiovascular Risk
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age54-75
SponsorMilton S. Hershey Medical Center
About this trial
To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It is hypothesized that estrogen deficiency increases BP, SNA and the pathway activities of the key pro-inflammatory mediators. Those effects are impacted through the downregulation of the estrogen receptor.
Eligibility criteria
Qualifiers
Age 54-75 years
Healthy participants who are capable of giving informed consent
Classified as postmenopausal or stop having period >1year or had a full hysterectomy surgery
Any race or ethnicity
Disqualifiers
<54 or >75 years
Medications that could alter cardiovascular, thermoregulatory, or peripheral vascular control (e.g. Angiotensin converting enzyme inhibitors, statins, beta blockers, etc.);
Self-reported history of long-term menstrual irregularities, vaginal bleeding, or other gynecological conditions that could influence study outcomes
Use of hormone therapy during 6 months prior to study enrollment
Trial design
Treatments tested in this trial
- Placebo
- Estradiol
Treatment groups
20 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov